Search

The article focuses on the effort to require immunization for the coronavirus disease COVID-19 in American schools as of August 2021. Topics include the surge in the delta variant of the virus, the lagging vaccination campaign for children under age 12, and the other diseases that require vaccines within schools, such as measles and polio.

The article focuses on the release of the vaccine for the coronavirus disease COVID-19 developed by biopharmaceutical company AstraZeneca Plc and the University of Oxford. Topics include the involvement of the U.S. National Institute of Allergy and Infectious Diseases (Niaid), the U.S. National Institutes of Health (NIH), and the Data and Safety Monitoring Board (DSMB).

The article reports on the long-term effects of COVID-19 infections. It mentions the ongoing symptoms of patients who survived the disease, the issue of continuing medical care for these survivors, and presents comments from several survivors from around the world.

Byline: Suzi Ring Law firm Macfarlanes drafted to investigate mining giant alleged financial irregularities in its Indonesian operations LAW FIRM MACFARLANES has been drafted in to advise mining giant Bumi [...]

Byline: Suzi Ring Administrators look at liquidating collapsed law firm with unsecured creditors likely to receive 11p for every £1 owed ADMINISTRATORS of Dewey & LeBoeuf's UK LLP have proposed [...]

Byline: Suzi Ring Italy's Pirola Pennuto Zei & Associati is set to become one of the first non-UK law firms to convert to an alternative business structure (ABS). Pirola - [...]

Jab-Nots: Vaccine Passports Will Exclude Less Fortunate Keywords: 280456Z@CN; ALLTOP; BIZWEEK; BUSINESS; CONS; CONSD; COS; DRG; EUROPE; EURTOP; GEN; GENTOP; GLOBALMACR; GOV; HAR; HEA; HUMANRIGHT; INDUSTRIES; LAW; LEI; LIFESTYLE; MED; NORTHAM; POL; PURSUITS; SOF; TEC; TLS; TMT; TOP; TRAVEL; UK; US; WORLD; WWTOP; WWTOPAM; WWTOPAS; WWTOPEU EN 280456Z@CN ALLTOP BIZWEEK BUSINESS CONS CONSD COS DRG EUROPE EURTOP GEN GENTOP GLOBALMACR GOV HAR HEA HUMANRIGHT INDUSTRIES LAW LEI LIFESTYLE MED NORTHAM POL PURSUITS SOF TEC TLS TMT TOP TRAVEL UK US WORLD WWTOP WWTOPAM WWTOPAS WWTOPEU Passes for travel risk leaving the poor and vulnerable behind. As vaccine rollouts accelerate in the U.K., U.S., and beyond, how do we open up safely, letting people who have protection and are demonstrably Covid-free return to pre-pandemic life without risk to the rest of the population?. [Extracted from the article]

The article describes problems facing pharmaceutical and biopharmaceutical company AstraZeneca as of early 2021. Particular focus is given to their Covid-19 vaccine, which was developed by the company in collaboration with the University of Oxford, which has been shown to be less effective than vaccines developed by Pfizer Inc. and Moderna Inc. The threat of viral variants is further plaguing vaccine development.

The article focuses on the vaccines being developed for the coronavirus disease COVID-19 as of November 23, 2020 and how they might be regulated by the United States (U.S.) Food and Drug Administration. Topics include the vaccine by pharmaceutical company Pfizer Inc. and its German partner BioNTech SE, the vaccine by biotechnology company Moderna Inc., and the vaccine by pharmaceutical company AstraZeneca Plc in partnership with the University of Oxford.

Obesity Revolution Chief Executive Officer Lars Fruergaard Jorgensen shrugged off the Wegovy supply worries. (Bloomberg) -- Novo Nordisk A/S said the supply of its blockbuster obesity medicine Wegovy will continue to be restricted in the US as the drugmaker struggles to expand production. [Extracted from the article]

In a separate interview, Novo Chief Executive Officer Lars Fruergaard Jorgensen said it "will be difficult" to fulfill demand for Wegovy because it's so high and an estimated one billion people are expected to have obesity by 2030. (Bloomberg) -- Novo Nordisk A/S plans to publish the detailed data from its key trial looking at the cardiovascular impact of its hit obesity drug at a US conference in November. The data will also provide more information on the longer-term use of Wegovy, also known as semaglutide, for weight loss. [Extracted from the article]

The Danish company made the comments even as it raised its profit and sales outlook for the year as demand for Wegovy and another related diabetes medicine fuel revenue growth. (Bloomberg) -- Novo Nordisk A/S said the supply of its blockbuster obesity medicine Wegovy will continue to be restricted in the US as the drugmaker struggles to expand production. [Extracted from the article]

(Bloomberg) -- Novo Nordisk A/S said the supply of its blockbuster obesity medicine Wegovy will continue to be restricted in the US as the drugmaker struggles to increase capacity. The Danish company made the comments even as it raised its profit and sales outlook for the year as demand for Wegovy and another related diabetes medicine used for weight loss fuel revenue growth. [Extracted from the article]

Demand for the diet drug Wegovy surged beyond analysts' estimates last quarter, though revenue was held back by supply constraints. (Bloomberg) -- Novo Nordisk A/S raised its outlook for the year, fueled by demand for its obesity blockbusters. [Extracted from the article]

(Bloomberg) -- Novo Nordisk A/S's blockbuster obesity medicine Wegovy reduced the risk of heart attacks and strokes in a highly anticipated study, buoying shares of the Danish drugmaker and the US maker of a potential rival treatment, Eli Lilly & Co. People with obesity or overweight and a history of heart issues taking the Novo drug were 20% less likely to suffer a cardiovascular event than those who took a placebo, the Danish drugmaker said on Tuesday. Lilly surged as much as 10% in early trading after the company raised its outlook on the back of stronger-than-expected sales of Mounjaro, a diabetes drug that's expected to be approved for obesity soon. [Extracted from the article]

(Bloomberg) -- AstraZeneca Plc has agreed to buy a portfolio of rare disease gene therapies from Pfizer Inc. as the UK drug company looks to the future for its next areas of revenue and growth. Shares in Astra and partner on the drug Daiichi Sankyo Co. fell sharply earlier this month following initial indications that raised questions about the drug's effectiveness and safety. [Extracted from the article]

Still, questions remain for Astra on the trial results from its potentially game-changing lung cancer drug, datopotamab deruxtecan, that could overtake standard chemotherapy as a treatment option. (Bloomberg) -- AstraZeneca Plc has agreed to buy a portfolio of rare disease gene therapies from Pfizer Inc. as the UK drug company reported sales and profit that beat analysts' estimates in the second quarter. [Extracted from the article]

(Bloomberg) -- AstraZeneca Plc has agreed to buy a portfolio of rare disease gene therapies from Pfizer Inc. as the British drug company reported sales and profit that beat analysts' estimates in the second quarter. AstraZeneca also reported that earnings per share, excluding some costs, rose to $2.15 in the second quarter, the drugmaker said in a statement Friday. [Extracted from the article]

(Bloomberg) -- Drugs from Novo Nordisk and Eli Lilly Co. are being investigated by the UK medicines regulator over patient reports of suicidal thoughts, shortly after Europe's watchdog opened a probe into the same issue. The UK Medicines & Healthcare products Regulatory Agency has received several reports of suspected adverse drug reactions associated with such behavior possibly related to semaglutide - the active ingredient in Novo's diabetes and weight-loss drugs Ozempic and Wegovy, the agency said in a statement Wednesday. [Extracted from the article]

Litigation related to the drugmaker's blockbuster heartburn medication Zantac over allegations it caused cancer continue to hang over the UK drugmaker, despite GSK settling the first bellweather case in California last month. GSK's current rollout of RSV vaccine Arexvy is a key focus, but ongoing Zantac litigation continues to dampen investor sentiment. [Extracted from the article]

Scientists and doctors have been searching for RSV vaccines and drugs for decades to tackle a disease that hospitalizes up to 80,000 children under age five every year in the US. (Bloomberg) -- AstraZeneca Plc and Sanofi's drug for RSV in infants was approved in the US, the first-ever preventive intended for wide use against a common but dangerous virus in young children. [Extracted from the article]

(Bloomberg) -- The European Union's drug regulator expanded its investigation into a possible risk of suicidal thoughts associated with a new class of weight-loss medicines and a separate analysis found that most patients stopped taking the medications after a year. Five Medicines The European regulator named five GLP-1 medicines that are being investigated, including dulaglutide, the active ingredient in Lilly's blockbuster drug Trulicity for type 2 diabetes. [Extracted from the article]

(Bloomberg) -- Novo Nordisk A/S and Eli Lilly & Co fell after the EU's drug regulator widened its investigation into weight loss medicines and a separate analysis found that most patients stopped taking the medications after a year. Five Medicines The European regulator named five GLP-1 medicines that are being investigated, including dulaglutide, the active ingredient in Lilly's blockbuster drug Trulicity for type 2 diabetes. [Extracted from the article]

(Bloomberg) -- Novo Nordisk A/S and Eli Lilly & Co fell Tuesday after the EU's drug regulator widened its investigation into weight loss medicines and a separate analysis found that most patients stopped taking the medications after a year. The European regulator named five GLP-1 medicines that are being investigated, including dulaglutide, the active ingredient in Lilly's blockbuster drug Trulicity for type 2 diabetes. [Extracted from the article]

(Bloomberg) -- The European Union's drug regulator expanded its investigation into a possible risk of suicidal thoughts associated with a new class of weight-loss drugs after receiving 150 reports. The European Medicines Agency is looking at all drugs known as GLP-1 receptor agonists after initially focusing on side effects linked to Novo Nordisk A/S's Wegovy, Ozempic and Saxenda, the agency said in a statement Tuesday. [Extracted from the article]

(Bloomberg) -- Novo Nordisk A/S's weight-loss medications are under investigation by the European Union's drugs regulator after a small number of reports of suicidal risks were referred to the watchdog. Novo has entered the limelight over the last two years after Wegovy and sister diabetes drug Ozempic were found to induce significant weight loss, with celebrities and high-profile business personalities openly discussing their use of them. [Extracted from the article]

Novo has entered the limelight over the last two years after Wegovy and sister diabetes drug Ozempic were found to induce significant weight loss, with celebrities and high-profile business personalities openly discussing their use of them. (Bloomberg) -- Novo Nordisk A/S's weight-loss medications are under investigation by the European Union's drugs regulator after a small number of reports of suicidal risks were referred to the watchdog. [Extracted from the article]

(Bloomberg) -- Weight-loss medications from Novo Nordisk A/S are being investigated by the European Union's drugs regulator after several reports of suicidal risks were referred to the watchdog. Novo's latest hit weight-loss drug Wegovy also contains semaglutide. [Extracted from the article]

The medicines' success so far puts them on track to be some of the pharma industry's best-selling drugs, causing supply shortages and forcing Novo to ration starter doses to favor existing users over newcomers. (Bloomberg) -- Two years and more than a million prescriptions after Wegovy first went on sale, there's one taboo question for some doctors who prescribe the hit obesity drug: When can patients stop taking it?. [Extracted from the article]

(Bloomberg) -- The UK's National Health Service has "strikingly low" levels of key clinical staff and worse health outcomes for diseases like cancer compared with other similar countries, according to a report. The author of the report looked at how the UK's health system stacks up against 18 other countries, including the US, Germany, and Japan. [Extracted from the article]

Both Pfizer and GSK have said they expect to have supply available ahead of the next RSV season this fall. (Bloomberg) -- Shots from Pfizer Inc. and GSK Plc that prevent respiratory syncytial virus received backing from a panel of US public health advisers for use in older adults, paving the way for the preventives to be used in a vulnerable population. [Extracted from the article]

Prior to splitting off its consumer business last year, GSK cited RSV among its major growth drivers for the standalone vaccines and pharma business, with sales potential of more than £3 billion ($3.8 billion) annually. (Bloomberg) -- GSK Plc's newly authorized vaccine against respiratory syncytial virus provides protection across two seasons, potentially giving the UK drugmaker an edge over rivals. [Extracted from the article]

(Bloomberg) -- Novo Nordisk A/S is spending 15.9 billion Danish kroner ($2.29 billion) to expand production facilities in Denmark as the obesity drug manufacturer looks to ensure capacity for its future portfolio. The investment in Hillerød, Denmark is planned to create additional production for its pipeline drugs to fight serious chronic diseases, Novo said in a statement Monday. Drugs under development in the company's portfolio include medicines aimed at treating heart and sickle-cell disease. [Extracted from the article]

(Bloomberg) -- AstraZeneca Plc entered a collaboration with UK biotech Quell Therapeutics potentially worth more than $2 billion to develop cell therapies against major autoimmune diseases. The deal aims to leverage Quell's proprietary cell-therapy engineering platform with Astra's commercial experience. [Extracted from the article]

Scientists and doctors have been looking for vaccines and drugs against RSV, which also creates a large health burden in older people, for more than 60 years. (Bloomberg) -- AstraZeneca Plc's and Sanofi's drug to prevent respiratory syncytial virus won support from a US regulatory panel for use in infants, potentially adding to a group of breakthrough products set to reach pharmacy shelves this year. [Extracted from the article]

(Bloomberg) -- The UK is looking into making obesity drugs more widely available, as a new class of medicines show potential for easing the burden of weight-related diseases on the healthcare system. Millions of people globally are clamoring for obesity drugs after trials have shown medicines like Wegovy can help a person shed as much as 15% of body weight. [Extracted from the article]

(Bloomberg) -- Big businesses are shunning a crucial meeting to decide the future of the Confederation of British Industry, the lobby group facing potential collapse amid a sexual assault scandal. Carl Ennis, chief executive of Siemens, UK and Ireland, said the company would vote to give the CBI a mandate to continue. [Extracted from the article]

Sunak made a leadership pledge last year to slash taxes by 20% by the end of the decade, as he attempted to rival tax cuts promised by former Prime Minister Liz Truss. (Bloomberg) -- UK Prime Minister Rishi Sunak wants to cut National Insurance or income tax by as much as two pence (2.5 cents) before next year's general election to try and encourage people back to work, according to the Telegraph. [Extracted from the article]

This data is important because it's "bringing a precision medicine into an early stage of lung cancer." (Bloomberg) -- A blockbuster lung cancer drug from AstraZeneca Plc was found to improve survival by more than half in a subset of patients, boosting the company's ambitions to widen its oncology portfolio across as many groups and indications as possible. [Extracted from the article]

HMPV is often misdiagnosed as respiratory syncytial virus, Lingelbach said, and with the first-ever vaccines against RSV coming online this year the market is moving toward HMPV-RSV combination vaccines. Outside of a sale, Valneva is looking at transferring manufacturing from its original Scottish plant - Manson - to the Almeida facility and repurposing the older factory, Lingelbach said. (Bloomberg) -- Valneva SE has been approached by about a dozen potential buyers for its Scottish manufacturing site, according to the company's chief executive officer, after the French drugmaker said earlier this month it was mulling a sale. [Extracted from the article]

Britain is "absolutely open for business in really high-value science and technology industries", Smith said, citing the case of Oxford Nanopore Technologies Ltd., a DNA-sequencing company that made one of the UK's best-ever market debuts in 2021. (Bloomberg) -- Britain is well-placed to attract high-growth companies, despite increasing global competition due to interventions such as US President Joe Biden's massive package of subsidies and tax breaks for green industries, a government minister said. [Extracted from the article]

RSV, characterized by an acute respiratory illness, affects an estimated 64 million people globally and causes 160,000 deaths each year, according to the US National Institute of Allergy and Infectious Diseases. (Bloomberg) -- For 60 years, doctors and scientists searched for a vaccine against a common virus that, while sometimes deadly, is little known to the public. [Extracted from the article]

The FDA clearance also gives the UK drugmaker a short lead time to push its product before Pfizer gains permission to sell a rival shot, a decision also expected in May. (Bloomberg) -- GSK Plc's vaccine for respiratory syncytial virus won clearance from US regulators, giving the drugmaker an edge in its race against Pfizer Inc. as its product becomes the first shot approved to protect older adults from the lung disease. [Extracted from the article]

Along with 25 other experts, Iqbal has been co-opted onto a new UK government panel to assess the risk of the bird flu epidemic on humans as part of its preparations for the next pandemic. Cambodia, which recorded 37 bird flu deaths in the decade up to 2014, has finetuned its pandemic preparedness since Covid. (Bloomberg) -- If you want to know how the world is preparing for the next global pandemic look at Rolaing, a Cambodian village located on a tributary of the Mekong River. [Extracted from the article]